

## Special Issue

# The Future of the Cancer Treatment: The Immunotherapy Next Generation

### Message from the Guest Editors

After decades of intense effort, the therapeutics that leverage the immune system to contrast the cancer, have now conclusively demonstrated their effectiveness. However, the search for novel methods to improve immunotherapy continues without any reduction in intensity or strength. In this way, the use of small molecule immunotherapeutic approaches for the treatment of cancer are especially interesting. Small molecules can either reduce immune suppression in the tumor milieu or enhance the activation of cytotoxic lymphocyte responses to the tumor, and might be used as monotherapies or combined with other cancer therapies to increase and broaden their efficacy. Insight into the more promising immunotherapeutic approaches in the form of original research articles or reviews in all areas of cancer, experimental designs, and therapeutic approaches are welcome. It is a pleasure to invite you to submit a manuscript to this Special Issue. Regular articles, communications, and reviews are all welcome.

---

### Guest Editors

Dr. Amedeo Amedei

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

Dr. Elena Niccolai

Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy

---

### Deadline for manuscript submissions

closed (30 November 2020)



## Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/si/27802](https://mdpi.com/si/27802)

*Molecules*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[molecules@mdpi.com](mailto:molecules@mdpi.com)

[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)





# Molecules

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.6  
CiteScore 8.6  
Indexed in PubMed



[mdpi.com/journal/  
molecules](https://mdpi.com/journal/molecules)



## About the Journal

### Message from the Editor-in-Chief

As the premier open access journal dedicated to molecular chemistry, now in its 30th year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts, and novel materials. Pushing the boundaries of the discipline, we invite papers on all major fields of molecular chemistry and multidisciplinary topics bridging chemistry with biology, physics, and materials science, as well as timely reviews and topical issues on cutting-edge fields in all of these areas.

---

### Editor-in-Chief

Prof. Dr. Thomas J. Schmidt

Institute of Pharmaceutical Biology and Phytochemistry, University of Münster, Corrensstrasse 48, D-48149 Münster, Germany

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Reaxys, CaPlus / SciFinder, MarInLit, AGRIS, and other databases.

#### Journal Rank:

JCR - Q2 (Biochemistry and Molecular Biology) / CiteScore - Q1 (Organic Chemistry)

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.1 days after submission; acceptance to publication is undertaken in 2.6 days (median values for papers published in this journal in the second half of 2025).